Most recent studies conducted to validate the ELN 2022 were also limited in their patient selection, as some included patients on non-intense chemotherapy regimens, distinctly younger patient populations than the median age of 68 years, and very low numbers of AML TP53 mutant patients. Here, TP53 is linked to acute myeloid leukemia.